Cardea Services

cardeaservices.org

Cardea is a national organization with offices in Oakland, California; Austin, Texas; and Seattle, Washington. For more than 40 years, we have provided training, organizational development, and research and evaluation services to improve organizations’ abilities to deliver accessible, high quality, culturally proficient, and compassionate services to their clients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

IDC: PHARMACEUTICAL INDUSTRY UPS INVENTORY LEVELS AS OTIF RATES FALL

Pharmaceutical | November 19, 2020

news image

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administ...

Read More

Pharma Tech

JANSSEN SEEKS EUROPEAN COMMISSION APPROVAL OF A NEW INDICATION FOR CARVYKTI® FOR THE EARLIER TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY

Globenewswire | June 01, 2023

news image

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma. “The previous European Commission approval recognised the potential for cilta-cel to positively impact outcomes for peop...

Read More

Business Insights

ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES

Ascletis Pharma Inc. | February 14, 2022

news image

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Read More

ALZECURE PHARMA PROVIDES A SCIENTIFIC UPDATE ON ALZHEIMER'S DISEASE AND THE ALZSTATIN PROJECT PLATFORM

AlzeCure Pharma | September 28, 2020

news image

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...

Read More
news image

Pharma Tech

IDC: PHARMACEUTICAL INDUSTRY UPS INVENTORY LEVELS AS OTIF RATES FALL

Pharmaceutical | November 19, 2020

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administ...

Read More
news image

Pharma Tech

JANSSEN SEEKS EUROPEAN COMMISSION APPROVAL OF A NEW INDICATION FOR CARVYKTI® FOR THE EARLIER TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY

Globenewswire | June 01, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new indication for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma. “The previous European Commission approval recognised the potential for cilta-cel to positively impact outcomes for peop...

Read More
news image

Business Insights

ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES

Ascletis Pharma Inc. | February 14, 2022

Ascletis Pharma Inc.announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companies, including major multi-national...

Read More
news image

ALZECURE PHARMA PROVIDES A SCIENTIFIC UPDATE ON ALZHEIMER'S DISEASE AND THE ALZSTATIN PROJECT PLATFORM

AlzeCure Pharma | September 28, 2020

CEO Martin Jönsson and CSO Johan Sandin will, among other things, present the pharmaceutical platform Alzstatin and the research behind it. Within the Alzstatin platform, AlzeCure develops disease-modifying and preventive drugs for Alzheimer's disease that focus on reducing the production of toxic amyloid beta (Aβ) in the brain. Henrik Zetterberg, chief physician and professor at the Department of Neuroscience and Physiology at Sahlgrenska Academy and professor at University Colleg...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us